
OmniAb, Inc. (OABI) Stock Ticker
OABI right now
Market factors today
Unlock the full OABI picture
About OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI stock facts
| Ticker symbol | OABI |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $668.3M |
| CEO | Matthew W. Foehr |
| Employees | 89 |
| Headquarters | EmeryVille, CA, US |
| IPO date | 2021-09-30 |
| Website | www.omniab.com |
What you can see for OABI on Tickr
Live OABI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OABI report.
Rankings
FAQ
What is the ticker symbol for OmniAb, Inc.?
The ticker symbol for OmniAb, Inc. is OABI, listed on the NASDAQ Global Market.
What is OABI?
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological…